Brief: Cogent Biosciences Announces Additional Clinical Data From Part 1 Of Its Ongoing Summit Trial

Cogent Biosciences

14/06/2024 12:41

June 14 (Reuters) - Cogent Biosciences Inc  COGT.O :
    * COGENT BIOSCIENCES ANNOUNCES ADDITIONAL CLINICAL DATA FROM
PART
1 OF ITS ONGOING SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN
PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM)
    * PATIENTS TREATED WITH 100 MG BEZUCLASTINIB SHOWED
SUBSTANTIAL
REDUCTION IN THEIR MOST SEVERE SYMPTOMS AND MAST CELL REACTIONS
    * ON TRACK TO COMPLETE ENROLLMENT IN REGISTRATION-DIRECTED
SUMMIT
PART 2 STUDY IN Q2 OF 2025, REPORT TOPLINE RESULTS BY YEAR-END
2025
    * SUMMIT TRIAL SHOWED CLINICALLY MEANINGFUL IMPROVEMENT IN
SKIN
SYMPTOMS AS WELL AS OBJECTIVE REDUCTION IN SKIN LESIONS
    * RECOMMENDED DOSE OF 100 MG DEMONSTRATES A FAVORABLE SAFETY
AND
TOLERABILITY PROFILE

Source text for Eikon:  ID:nGNX2jjDty 
Further company coverage:  COGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))